M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
Biotechnology company Allergy Therapeutics (AIM: AGY) announced on Monday that it has published Phase III trial data for its subcutaneous immunotherapy Grass MATA MPL in the journal Allergy. The study demonstrated a 20.3% reduction in Combined Symptom & Medication Score (CSMS) versus placebo...
If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search